Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
AssigneeYM Biosciences Australia Pty Ltd
InventorLawrence S. Zisman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating pulmonary arterial hypertension by administering a therapeutically effective amount of a selective JAK2 inhibitor to a patient in need thereof.
Claims20
A method of treating class I pulmonary hypertension (pulmonary arterial hypertension (PAH)), comprising administering a therapeutically effective amount of a selective JAK2 inhibitor to a patient in need thereof.
A method of reducing the occurrence of pulmonary arteriolar obstruction in a patient afflicted with class I pulmonary hypertension, comprising administering an effective amount of a selective JAK2 inhibitor to the patient.
Dependencies are inferred from the claim text.